PDCD1 and neoplasm: For these DC-based therapies, we may envisage therapeutic scenarios where CRC patients are treated with autologous DC, either as unloaded APC injected intratumorally (endogenous tumor vaccination) in combination with agents either inducing or enhancing tumor cell death [71,72], or as in vitro antigen loaded DC, and subsequently injected with anti-PD1 antibodies or other CPI to increase the antitumor response in selected combination therapies.